342 related articles for article (PubMed ID: 24602463)
1. Leveraging melanocortin pathways to treat glomerular diseases.
Gong R
Adv Chronic Kidney Dis; 2014 Mar; 21(2):134-51. PubMed ID: 24602463
[TBL] [Abstract][Full Text] [Related]
2. MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.
Qiao Y; Berg AL; Wang P; Ge Y; Quan S; Zhou S; Wang H; Liu Z; Gong R
Sci Rep; 2016 Jun; 6():27589. PubMed ID: 27270328
[TBL] [Abstract][Full Text] [Related]
3. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
[TBL] [Abstract][Full Text] [Related]
4. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.
Qiao Y; Wang P; Chang M; Chen B; Ge Y; Malhotra DK; Dworkin LD; Gong R
Clin Sci (Lond); 2020 Apr; 134(7):695-710. PubMed ID: 32167144
[TBL] [Abstract][Full Text] [Related]
5. Melanocortin 5 receptor signaling pathway in health and disease.
Xu Y; Guan X; Zhou R; Gong R
Cell Mol Life Sci; 2020 Oct; 77(19):3831-3840. PubMed ID: 32248247
[TBL] [Abstract][Full Text] [Related]
6. The renaissance of corticotropin therapy in proteinuric nephropathies.
Gong R
Nat Rev Nephrol; 2011 Dec; 8(2):122-8. PubMed ID: 22143333
[TBL] [Abstract][Full Text] [Related]
7. Melanocortin 1 receptor agonists reduce proteinuria.
Lindskog A; Ebefors K; Johansson ME; Stefánsson B; Granqvist A; Arnadottir M; Berg AL; Nyström J; Haraldsson B
J Am Soc Nephrol; 2010 Aug; 21(8):1290-8. PubMed ID: 20507942
[TBL] [Abstract][Full Text] [Related]
8. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.
Zietse R; Wenting GJ; Kramer P; Schalekamp MA; Weimar W
Clin Sci (Lond); 1992 Jun; 82(6):641-50. PubMed ID: 1320544
[TBL] [Abstract][Full Text] [Related]
9. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.
Madan A; Mijovic-Das S; Stankovic A; Teehan G; Milward AS; Khastgir A
BMC Nephrol; 2016 Mar; 17():37. PubMed ID: 27036111
[TBL] [Abstract][Full Text] [Related]
10. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.
Agrawal V; Prasad N; Jain M; Pandey R
Clin Exp Nephrol; 2013 Dec; 17(6):811-8. PubMed ID: 23377573
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy.
Yang Y; Gubler MC; Beaufils H
Nephron; 2002 Jul; 91(3):416-23. PubMed ID: 12119471
[TBL] [Abstract][Full Text] [Related]
12. Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities.
Chang M; Chen B; Shaffner J; Dworkin LD; Gong R
Front Physiol; 2021; 12():651236. PubMed ID: 33716796
[TBL] [Abstract][Full Text] [Related]
13. Immunoexpression of podocyte-associated proteins in acquired human glomerulopathies with nephrotic syndrome.
Wagrowska-Danilewicz M; Stasikowska O; Danilewicz M
Pol J Pathol; 2006; 57(1):17-21. PubMed ID: 16739878
[TBL] [Abstract][Full Text] [Related]
14. Ezrin--a useful factor in the prognosis of nephrotic syndrome in children: an immunohistochemical approach.
Ostalska-Nowicka D; Zachwieja J; Nowicki M; Kaczmarek E; Siwinska A; Witt M
J Clin Pathol; 2006 Sep; 59(9):916-20. PubMed ID: 16522749
[TBL] [Abstract][Full Text] [Related]
15. Characterizing Glomerular Barrier Dysfunction with Patient-Derived Serum in Glomerulus-on-a-Chip Models: Unveiling New Insights into Glomerulonephritis.
Kim SY; Choi YY; Kwon EJ; Seo S; Kim WY; Park SH; Park S; Chin HJ; Na KY; Kim S
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791159
[TBL] [Abstract][Full Text] [Related]
16. The role of B7-1 in proteinuria of glomerular origin.
Novelli R; Benigni A; Remuzzi G
Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
[TBL] [Abstract][Full Text] [Related]
17. The multifunctional human ocular melanocortin system.
Wu CS; Cioanca AV; Gelmi MC; Wen L; Di Girolamo N; Zhu L; Natoli R; Conway RM; Petsoglou C; Jager MJ; McCluskey PJ; Madigan MC
Prog Retin Eye Res; 2023 Jul; 95():101187. PubMed ID: 37217094
[TBL] [Abstract][Full Text] [Related]
18. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.
Bomback AS; Tumlin JA; Baranski J; Bourdeau JE; Besarab A; Appel AS; Radhakrishnan J; Appel GB
Drug Des Devel Ther; 2011 Mar; 5():147-53. PubMed ID: 21448451
[TBL] [Abstract][Full Text] [Related]
19. Primary glomerular disease: to treat or not to treat.
Donadio JV
Contrib Nephrol; 1982; 33():86-103. PubMed ID: 7116871
[No Abstract] [Full Text] [Related]
20. Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases.
Manabe S; Nitta K; Nagata M
Contrib Nephrol; 2018; 195():131-142. PubMed ID: 29734158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
